+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of open-label iptacopan in adults with primary IgA nephropathy who have completed earlier clinical trials CLNP023X2203 or CLNP023A2301. This Phase III rollover extension program allows participants to continue treatment while gathering additional data on the drugs effects over time. The study aims to assess the ongoing impact of iptacopan on disease progression until marketing authorization or other specified conditions are met. Participants receive iptacopan capsules at a dose of 200 mg taken orally twice daily. Treatment continues until one of several conditions occurs, including completion of 3 years from the last participants first visit, loss of benefit as judged by the investigator, a change in the drugs benefit-risk profile, need for dialysis or kidney transplant, or drug availability through commercial channels. This open-label design provides continuous access to iptacopan while monitoring long-term effects. During the study, participants undergo safety assessments including monitoring for adverse events, vital sign changes, ECG abnormalities, and laboratory test results from the first dose until 7 days after the last dose. Efficacy evaluations are conducted every 6 months to track kidney function and proteinuria levels. The total participation period may last up to three years, offering detailed data on the drugs long-term safety and clinical impact in primary IgA nephropathy.

Age: 18Years - 100YearsAll GendersPhase 3
161 locations
E

Actively Recruiting

Researchers are evaluating the use of mirikizumab in children and adolescents aged 2 to 17 years with moderately to severely active Crohns disease. The study aims to assess the drugs effectiveness, safety, tolerability, and how well it is absorbed in the body. This phase 3 clinical trial involves participants with confirmed Crohns disease or fistulizing Crohns disease who have shown an inadequate response or intolerance to at least one prior medication. Participants will receive mirikizumab intravenously or subcutaneously, with dosing based on their weight category. The study includes a 12-week induction period, followed by a maintenance phase lasting from week 12 to week 52. After the treatment periods, there is a safety follow-up period lasting up to 16 weeks. Overall, the study will last approximately 74 weeks and may involve up to 19 visits. Throughout the study, participants will undergo various assessments including clinical response evaluations using the Pediatric Crohns Disease Activity Index PCDAI and endoscopic scoring. Researchers will monitor changes in inflammatory markers such as C-reactive protein and fecal calprotectin, as well as pharmacokinetic measures of mirikizumab. Safety and tolerability will be tracked during the follow-up period, with all evaluations scheduled at multiple timepoints throughout the study.

Age: 2Years - 17YearsAll GendersPhase 3
81 locations
N

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Labour Care Guide LCG, a new tool designed by the World Health Organization to improve the quality and safety of care during childbirth by replacing the previous WHO partograph. This trial aims to test the LCGs effect on labor interventions and maternal and neonatal outcomes in Norway, focusing especially on cesarean section rates and womens experience of labor. The study is important because the LCG has not yet been tested in high-income settings like Norway, and the results will guide possible national implementation. The trial uses a stepped wedge multicenter cluster randomized design involving ten hospitals across Norway. Initially, all sites will use the WHO partograph as standard care, then switch to using the LCG according to a randomized schedule. The study consists of three parts developing and testing an electronic version of the LCG, conducting the randomized trial to compare outcomes using the LCG versus the partograph, and surveying women about their childbirth experience using a questionnaire. Women with planned vaginal deliveries will be included unless they opt out. Participants will be monitored throughout labor using either the WHO partograph or the LCG depending on the hospitals phase in the trial. Researchers will collect data on labor interventions, maternal health, neonatal outcomes, and childbirth experience. Outcomes measured include cesarean section rates, instrumental vaginal delivery, perineal tears, postpartum hemorrhage, oxytocin use, pain relief methods, fetal monitoring, neonatal Apgar scores, and neonatal intensive care admissions. The trial will last 18 to 20 months, with thorough documentation and local coordinators ensuring adherence to the protocol.

Age: 18Years +FEMALEPhase Not Applicable
10 locations